Angiosarcoma is a rare malignant tumor that starts in endothelial cells, which form the inner lining of blood vessels. It is known for its aggressive behavior, rapid progression and poor prognosis, making it a particularly challenging cancer to treat.

The collaboration will leverage Tempus’ robust datasets and compute and analytical resources to deepen understanding of angiosarcoma biology and accelerate research. This includes Tempus’ approximately 600 de-identified angiosarcoma records, each with paired DNA and RNA sequencing data, along with associated de-identified clinical information where available, creating one of the largest known disease-specific molecular datasets in angiosarcoma.

For a cancer diagnosed in only about 1,000 people in the U.S. each year, this initiative could help researchers identify biological patterns and potential therapeutic opportunities that are difficult to detect in smaller, more fragmented datasets. Key challenges in studying rare cancers include the lack of molecular understanding, limited access to data and the absence of effective pre-clinical models.